Self-assembled polypeptides for antibody detection

The patent introduces self-assembled polypeptides as intermediary capture agents that specifically bind to target antibodies. These polypeptides are engineered with high affinity and specificity for the antibodies of interest, enabling sensitive detection without requiring complex sample preparation or multiple washing steps. The self-assembled nature of these polypeptides provides a stable, reproducible platform that enhances detection sensitivity while maintaining procedural simplicity.

The patent employs self-assembled polypeptides that are pre-engineered and pre-immobilized on detection surfaces, creating a ready-to-use detection platform. This preliminary preparation of high-affinity binding agents eliminates the need for time-consuming sample processing steps and multiple washing cycles required by MAIPA. The pre-assembled polypeptide structures provide immediate, specific binding capability that maintains high detection specificity while dramatically reducing assay time and labor requirements.

The patent utilizes self-assembled polypeptides with localized, high-density binding sites that concentrate detection capability in a small volume. These polypeptides are engineered with multiple antibody-binding domains arranged in optimal spatial configurations, creating local regions of extremely high binding affinity. This localized concentration of binding activity enables accurate detection using minimal blood sample volumes, as the polypeptides efficiently capture target antibodies from small samples without requiring the large volumes needed by traditional MAIPA methods.